ANXA6 and cancer: In regard to the potential of AnxA6 levels as a marker to predict cancer recurrence and chemotherapy response, its downregulation sensitized TNBC cells to EGFR-TKIs and was associated with poorer overall and distant metastasis-free survival [239,247].